Suggestions
Nazli Azimi
BIOTECHNOLOGY EXECUTIVE | Independent Board Member | Advisor | Investor
Nazli Azimi is a seasoned scientist entrepreneur with a proven track record of successfully launching and exiting two biotech companies.
She excels in transforming innovative ideas into prosperous businesses and possesses a diverse skill set encompassing all aspects of a biotech startup - from idea inception to exit strategies.
Her expertise lies in various areas including fundraising, IP evaluation, team building, FDA regulatory pathways, and M&A negotiations.
As the Chairwoman at the Terasaki Institute of Biomedical Innovation, Nazli Azimi plays a pivotal role in fostering translational research and entrepreneurship, guiding the leadership team in identifying high-value projects and facilitating spin-outs.
Additionally, she serves as an Independent board member for Zehna Therapeutics and acts as an advisor to a biotechnology-focused fund.
With a background in PharmD and a PhD, complemented by a post-doctoral fellowship in Immunology from the National Institutes of Health, Nazli Azimi boasts a profound understanding of immunology, oncology, virology, and neurological diseases.
She is the co-inventor of the Bioniz platform technology, which is fortified by over 45 patents, exemplifying her innovative prowess in the field.
Throughout her career, she has authored more than 50 peer-reviewed publications, establishing herself as a leading authority in the realm of biotechnology.
Her entrepreneurial endeavors are underpinned by unique competencies such as entrepreneurship based on novel technologies, IP strategy, market feasibility analysis, team leadership, regulatory approvals, clinical trials management, and corporate structure development.
Nazli Azimi's aspirational leadership style fosters personal growth and cultivates a culture of learning and excellence within organizations.
She is known for her ability to build consensus, bringing individuals from diverse backgrounds together to work efficiently towards common goals.
With a rich educational background that includes a PharmD from the University of Tehran and a Fellowship in Immunology from the University of Maryland, Nazli Azimi combines academic rigor with practical experience.
She has held various key positions in renowned organizations such as the Fred Hutchinson Cancer Research Center, where she served as a Research Scientist in the Virology Program.
Nazli Azimi's multifaceted roles, from founding and presiding over biotech companies to serving as a trusted advisor and board member, underscore her versatile expertise and significant contributions to the biotechnology sector.
Highlights
I joined the Board of Directors of the cultivated meat start up, Omeat, because I was drawn to the simplicity and yet novelty of the Company’s core idea for growing cultivated meat. Omeat’s founder, Ali Khademhosseini, is a scientist entrepreneur who comes from Bob Langer’s lab at MIT and is a leader in tissue engineering for medical applications. His prior research experience led him to envision Omeat’s technology that focuses on environment and sustainability which could have a much broader impact than medical applications. Like Ali, I am a scientist entrepreneur and appreciate the ingenuity in his thinking. I am happy to see this view is reflected in this article in the Fast Company. I encourage you to read it.
I am happy to announce that I have been working with the team at Omeat as an advisor and independent board member for the past year. Omeat is a groundbreaking cultivated meat company which was founded by former MIT professor and world-renowned tissue engineer expert, Dr. Ali Khademhosseini. Ali and his experienced team have been working in stealth mode for the past 3 years to advance a technology that allows for the cultivation of real meat (not plant-based) in a cost-effective and sustainable way. The cultivated meat movement has gained momentum in the past decade in order to address two main issues: the negative environmental impact of large-scale animal farming and animal cruelty. The majority of cultivated meat companies are using a plant-based approach to create a “meat-like” product. While this approach generally addresses these two issues by removing animal farming and slaughter from the equation, it creates a product that is not real meat and does not have its taste and texture.
In contrast, Omeat has created a product that is real meat by using a radically innovative approach. It centers around the cow itself – but not to be slaughtered for its meat. Omeat cows roam freely in a sustainably maintained organic farm. A very small muscle tissue is obtained from the cows using a safe procedure. Meat cells are grown in a medium that is supplemented by cows’ own plasma, a nutrient fluid that is collected from the cows in a safe and humane way. Both tissue and plasma collections are procedures that commonly, safely, and non-invasively used in humans in medical practice. If it is safe for humans, it is safe for animals too. Using this novel approach, one cow provides many cows’ worth of meat annually. This means Omeat can feed the planet with only a fraction of the current number of animals used in beef production.
Omeat has found an elegant solution to solve environmental damage and animal cruelty. Its farming is small scale and sustainable, and in harmony with nature. It also eliminates animal slaughter altogether. Since all the resources for growing this meat come from the farm itself, the product is affordable unlike many other market alternatives. Therefore, it provides an option for those of us who like to eat real meat but don’t like the negative environmental impact of animal farming or animal slaughter.
I am excited about the future of this company and am glad to have the opportunity to help make a meaningful impact on our environment. #technology #environment #sustainable #farming #cultivatedmeat
